Home Health and Hospice EBITDA Multiples: 2026 Report

The home health and hospice sectors remain among the most active segments in healthcare services M&A. An aging U.S. population, continued migration of care into the home, and strong demand for cost-effective post-acute care models continue to attract both strategic acquirers and private equity investors. At the same time, the valuation environment in 2026 is more disciplined than during the post-pandemic transaction surge. Buyers are placing greater emphasis on sustainable margins, compliance readiness, and operational stability rather than simply pursuing growth.

Across transactions, valuation is most commonly expressed as a multiple of adjusted EBITDA, which allows buyers to compare healthcare businesses across different markets and operating models. EBITDA removes the effects of financing decisions and accounting adjustments, making it the primary benchmark used to value home health and hospice providers while highlighting the importance of earnings quality, payer stability, and clinical performance.

EBITDA Multiples Remain the Primary Pricing Benchmark

Most transactions in the home health and hospice sectors are priced using adjusted EBITDA multiples, which reflect both profitability and perceived risk. Buyers primarily focus on the sustainability and documentation of EBITDA when evaluating acquisition targets.

Buyers do not pay simply for revenue scale. They pay for defensible operating cash flow supported by strong clinical and operational infrastructure.

These ranges illustrate how strongly scale and operational maturity influence valuation outcomes. Smaller founder-owned agencies tend to trade at lower multiples because they often rely heavily on owner involvement and lack the infrastructure required for rapid expansion. By contrast, larger multi-branch organizations with experienced leadership teams and standardized clinical operations often command higher multiples due to their ability to scale.

Market Conditions Shaping 2026 Valuations

The broader M&A environment for home health and hospice has evolved significantly over the past few years. According to Stoneridge Partners, the “growth at all costs” investment mindset that dominated the post-pandemic deal market has largely disappeared. Instead, investors are prioritizing predictable earnings, operational discipline, and regulatory compliance.

While buyer demand for quality agencies remains strong, investors are more selective about the assets they pursue. This has created a widening valuation gap between premium assets and smaller or operationally weaker agencies.

In practice, this means buyers now place greater emphasis on:

Organizations that can demonstrate strength in these areas are significantly more likely to attract competitive bidding from strategic acquirers and private equity groups.

The operational characteristics below increasingly influence valuation multiples, buyer interest levels, and deal timelines.

Platform vs. Tuck-In Acquisitions

Another major determinant of valuation multiples is whether an agency is considered a platform acquisition or a tuck-in acquisition.

Platform assets (larger organizations with strong management teams and scalable infrastructure) are often pursued by private equity investors seeking to build regional or national healthcare platforms. These businesses tend to attract multiple bidders and higher valuation multiples.

Tuck-in acquisitions, on the other hand, are smaller agencies that are integrated into an existing platform to expand geographic coverage or strengthen referral networks. While these deals remain common, they generally trade at lower multiples because the buyer already has infrastructure in place.

This distinction has become increasingly important as investors prioritize scalable organizations capable of supporting regional growth strategies.

Payer Mix and Reimbursement Risk

Payer mix is another critical determinant of valuation multiples in both hospice and home health transactions. Traditional Medicare fee-for-service reimbursement remains the most attractive payer source for buyers because of its relative stability and predictable reimbursement rates. However, the rapid growth of Medicare Advantage enrollment is beginning to reshape the valuation landscape.

Medicare Advantage plans often reimburse providers at lower rates than traditional Medicare. Agencies with a heavy concentration of MA patients may therefore face margin pressure, which can reduce valuation multiples. Conversely, agencies that maintain a balanced payer mix (including Medicare, commercial payers, and private pay sources) tend to be viewed as lower-risk investments.

Operational Drivers That Increase Multiples

While financial performance remains the foundation of valuation, operational characteristics often determine whether a business receives an average or premium multiple.

Agencies that command higher multiples often share several operational strengths. These include strong compliance programs, diversified referral networks, and stable clinical staffing. Investors increasingly view these factors as indicators of long-term operational durability.

The Role of Revenue in Healthcare Valuations

Although EBITDA multiples dominate healthcare M&A pricing, revenue still plays an important supporting role.

Revenue scale can help demonstrate market presence and operational stability. However, buyers typically treat revenue as a contextual indicator rather than a primary valuation metric.

This distinction explains why two agencies with identical revenue may receive very different valuations. A high-margin organization with stable referral sources and strong documentation will typically command both a higher enterprise value and a higher EBITDA multiple.

Outlook for Home Health and Hospice Valuations

Despite greater diligence and tighter underwriting standards, the long-term outlook for home health and hospice M&A remains strong. Structural healthcare trends continue to support investor interest in these sectors, including the rapid growth of the aging population and the ongoing shift of care away from hospital settings.

Demand for quality home health and hospice assets remains robust, particularly for organizations that demonstrate strong financial performance and operational stability.

However, the valuation environment in 2026 clearly rewards preparation. Agencies that maintain clean financial reporting, strong compliance programs, diversified payer relationships, and stable staffing structures are significantly more likely to achieve premium EBITDA multiples.

For owners considering a sale, recapitalization, or strategic partnership, the key takeaway is straightforward: buyers are not simply purchasing revenue; they are investing in sustainable, well-documented earnings supported by compliant, scalable healthcare operations.